There is no doubt that the results to date are meaningful as they have been accepted for presentation and agree with others sentiment.
The last paragraph is interesting "in parallel with the ongoing statistical analysis" they are also looking at the performance of test in the broadest possible range of kidney decline to maximise the clinical utility of the test. So does this mean the test could have value for not only CKD but for general kidney disease.
Ann: Proteomics International expands study with US big pharma, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $61.38M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.0¢ | 36.0¢ | $53.71K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 491 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 39195 | 2 |
View Market Depth
| Last trade - 15.55pm 07/08/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |